Prostate Cancer, Version 1.2014

Restricted access

The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.

Supplementary Materials

    • Supplemental Material (PDF 180 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 171 171 21
PDF Downloads 25 25 2
EPUB Downloads 0 0 0